Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]:
SEC Accession No. 0000950170-25-028376
Filing Date
2025-02-27
Accepted
2025-02-27 07:45:29
Documents
101
Period of Report
2024-12-31

Document Format Files

Seq Description Document Type Size
1 10-K verv-20241231.htm   iXBRL 10-K 3976853
2 EX-10.10 verv-ex10_10.htm EX-10.10 24600
3 EX-19.1 verv-ex19_1.htm EX-19.1 84342
4 EX-23.1 verv-ex23_1.htm EX-23.1 9141
5 EX-31.1 verv-ex31_1.htm EX-31.1 17565
6 EX-31.2 verv-ex31_2.htm EX-31.2 17557
7 EX-32.1 verv-ex32_1.htm EX-32.1 9999
8 EX-32.2 verv-ex32_2.htm EX-32.2 10182
9 GRAPHIC img245398681_0.jpg GRAPHIC 85423
10 GRAPHIC img245398681_1.jpg GRAPHIC 47074
  Complete submission text file 0000950170-25-028376.txt   14409725

Data Files

Seq Description Document Type Size
11 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT verv-20241231.xsd EX-101.SCH 1842411
104 EXTRACTED XBRL INSTANCE DOCUMENT verv-20241231_htm.xml XML 2401363
Mailing Address 201 BROOKLINE AVENUE SUITE 601 BOSTON MA 02215
Business Address 201 BROOKLINE AVENUE SUITE 601 BOSTON MA 02215 (978) 501-3026
Verve Therapeutics, Inc. (Filer) CIK: 0001840574 (see all company filings)

EIN.: 824800132 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-K | Act: 34 | File No.: 001-40489 | Film No.: 25673075
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)